Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA5A | P35218 | 4/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800609 | 1.00 | CYP2D6 (0.49) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL1800607 | 1.00 | CYP2D6 (0.49) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL17889827 | 1.00 | CYP2D6 (0.49) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL6376930 | 1.00 | CYP2D6 (0.49) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL1800610 | 1.00 | CYP2D6 (0.49) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL17736190 | 1.00 | CYP2D6 (0.49) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL17571769 | 1.00 | CYP2D6 (0.49) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL14307748 | 1.00 | CYP2D6 (0.49) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL314060 | 0.98 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10OGACA2 | |
| SCHEMBL4619592 | 0.98 | CYP2D6 (0.51) | CYP2D6THRBHSD17B10OGACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284388-A1 | ETHYL CELLULOSE BASED COATINGS FOR MICROENCAPSULATION OF NICOTINAMIDE RIBOSIDE AND OTHER NICOTINYL RIBOSIDE COMPOUNDS | Chromadex, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230348521-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | ELYSIUM HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11767314-B2 | Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same | CONOPCO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11629163-B2 | Methods of synthesizing nicotinamide riboside | ELYSIUM HEALTH, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3873415-A1 | BIOENERGETIC NICOTINIC ACID GLYCEROL ESTERS, COMPOSITIONS AND METHODS OF USING SAME | UNILEVER GLOBAL IP LIMITED (GB) | 2021-09-08 | — | — | EP | disclosed |
| US-20200140475-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | ELYSIUM HEALTH, INC. | 2020-05-07 | — | — | US | disclosed |
| WO-2019006262-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | ELYSIUM HEALTH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018033639-A1 | LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2018-02-22 | — | — | WO | disclosed |
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| US-6800629-B2 | VIRICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-20030130213-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1295890-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1256588-A1 | NOVEL PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THE SALTS AND INTERMEDIATES FOR THE PREPARATION OF BOTH | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1060182-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | Metabasis Therapeutics, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999045016-A9 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999045016-A2 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348521-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | NAMPT, NADK, NNT | CYP2D6 2669/4885THRB 1741/4885HSD17B10 658/4885 |
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | PNP, NUDT1, SLC29A1 | CYP2D6 1804/4885THRB 4801/4885HSD17B10 4454/4885 |
| US-20030130213-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | GTF3C5, EIF2AK2, GTF3C2 | CYP2D6 82/4885THRB 3824/4885HSD17B10 983/4885 |
| US-11767314-B2 | Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same | PRKAG1, PRKAB1, PRKAG2 | CYP2D6 4700/4885THRB 2014/4885HSD17B10 1391/4885 |
| US-11629163-B2 | Methods of synthesizing nicotinamide riboside | NAMPT, NADK, NNT | CYP2D6 2669/4885THRB 1741/4885HSD17B10 658/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | CYP2D6 172/4885THRB 235/4885HSD17B10 994/4885 |
| US-20200140475-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | NAMPT, NADK, NNT | CYP2D6 2669/4885THRB 1741/4885HSD17B10 658/4885 |
| US-20040235761-A1 | Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | CDK5, NT5C3B, CDK15 | CYP2D6 2222/4885THRB 2563/4885HSD17B10 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.